Biopsy Devices Market to Reach US$ 6.85 Billion by 2033 at 10.15% CAGR; North America Leads with 42% Share - Key Players: Becton, Dickinson and Company, Hologic Inc., Boston Scientific Corporation

The global biopsy devices market reached US$2.68 billion in 2025 and is expected to reach US$6.85 billion by 2033, growing at a CAGR of 10.15% during the forecast period 2026 to 2033. The market is expanding steadily as the demand for early and accurate disease diagnosis, particularly for cancer, continues to rise globally.

Market growth is driven by the increasing prevalence of cancer and other chronic diseases, growing awareness about early diagnosis, and advancements in minimally invasive diagnostic procedures. Biopsy devices play a critical role in obtaining tissue samples for accurate diagnosis and treatment planning, improving patient outcomes and clinical decision-making. In addition, technological advancements such as image-guided biopsy systems, robotic-assisted procedures, and vacuum-assisted biopsy devices are enhancing precision and efficiency. Rising healthcare expenditure, expanding diagnostic infrastructure, and increasing adoption of personalized medicine are further accelerating market adoption, positioning biopsy devices as a key component of modern diagnostic and oncology care.

Download a sample PDF of this report (get higher priority for a corporate email ID): - https://www.datamintelligence.com/download-sample/biopsy-devices-market?sai-v

Key Developments
✅ February 2026: Across North America, Europe, and the Asia Pacific, the increasing incidence of cancer and growing emphasis on early diagnosis accelerated demand for advanced biopsy devices, including minimally invasive and image-guided systems.

✅ January 2026: Globally, technological advancements such as robotic-assisted biopsy, vacuum-assisted biopsy, and AI-integrated imaging improved diagnostic accuracy and procedural efficiency.

✅ December 2025: Leading companies such as Hologic Inc., Becton Dickinson and Company, Boston Scientific Corporation, Cook Medical, and Argon Medical Devices expanded product portfolios focusing on precision, safety, and minimally invasive capabilities.

✅ November 2025: Rising adoption of liquid biopsy and needle-based biopsy procedures increased due to reduced patient discomfort and faster recovery times.

✅ October 2025: Companies intensified investments in automation, real-time imaging guidance, and disposable biopsy instruments to enhance workflow efficiency and reduce infection risks.

✅ September 2025: Across key regions including the United States, Germany, China, India, and Japan, growing healthcare infrastructure, screening programs, and awareness campaigns supported market expansion.

Key Players
Becton, Dickinson and Company | Hologic Inc. | Devicor Medical Products Inc. | Cook Medical | Boston Scientific Corporation | Intact Medical Corporation | Gallini Medical | TSK Laboratory Europe BV | Argon Medical Devices | Medtronic | Others

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=biopsy-devices-market?sai-v

Market Drivers
- Rising global prevalence of cancer is significantly driving demand for biopsy procedures, as they remain the gold standard for accurate diagnosis and staging.

- Increasing preference for minimally invasive procedures is boosting adoption of needle-based and image-guided biopsy devices due to reduced pain, faster recovery, and lower complication risks.

- Growing awareness of early disease detection and expanding cancer screening programs are accelerating the demand for biopsy diagnostics.

- Technological advancements such as vacuum-assisted, robotic-assisted, and image-guided biopsy systems are enhancing diagnostic accuracy and efficiency.

- Increasing incidence of chronic and lifestyle-related diseases requiring tissue analysis is contributing to sustained market growth.

- Expansion of healthcare infrastructure and diagnostic imaging centers in emerging economies is improving access to biopsy procedures.

- Rising demand for outpatient and point-of-care diagnostic solutions is supporting the adoption of portable and cost-effective biopsy devices.

Industry Developments
- Shift toward advanced minimally invasive biopsy techniques such as core needle and vacuum-assisted biopsies for improved diagnostic precision.

- Increasing integration of imaging technologies such as ultrasound, MRI, and stereotactic guidance to enhance targeting accuracy.

- Growing development of robotic-assisted and AI-enabled biopsy systems to improve procedural outcomes and efficiency.

- Rising adoption of liquid biopsy technologies as a complementary or alternative diagnostic approach.

- Expansion of biopsy procedures in ambulatory surgical centers due to cost efficiency and faster patient turnaround.

- Strategic investments by manufacturers in product innovation and global expansion to strengthen market presence.

- Increasing focus on personalized and precision diagnostics is driving innovation in biopsy device design and applications.

Regional Insights
North America 42% share: Dominates the market due to high cancer incidence, advanced healthcare infrastructure, strong reimbursement systems, and early adoption of innovative biopsy technologies.

Europe 25% share: Growth supported by increasing cancer screening programs, strong regulatory frameworks, and rising demand for minimally invasive diagnostic procedures.

Asia Pacific 23% share: Fastest-growing region driven by improving healthcare infrastructure, rising patient population, and increasing investments in diagnostic technologies in countries such as China and India.

Latin America 6% share: Emerging growth supported by expanding access to healthcare services and increasing awareness of early disease diagnosis.

Middle East & Africa 4% share: Gradual growth driven by healthcare modernization, improving diagnostic capabilities, and rising government healthcare initiatives.

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/biopsy-devices-market?sai-v

Key Segments
By Body Part
Breast biopsy devices represent the dominant segment, driven by the high prevalence of breast cancer and widespread screening programs that require early and accurate diagnosis. Lung biopsy devices also represent a significant segment, fueled by the rising incidence of lung cancer and increasing adoption of minimally invasive diagnostic procedures. Colorectal biopsy devices represent an important segment, supported by growing awareness and screening initiatives for colorectal cancer. Liver biopsy devices represent a steady segment, driven by increasing cases of liver diseases and cancers. Others represent a growing segment, including biopsy devices for kidney, prostate, and other organs, expanding diagnostic capabilities across specialties.

By Application
Interventional oncology represents the dominant segment, driven by the increasing use of biopsy procedures for cancer diagnosis, staging, and treatment planning. Gynecology also represents a significant segment, supported by rising screening and diagnostic procedures for cervical and uterine cancers. Urology represents an important segment, fueled by growing cases of prostate and bladder disorders requiring biopsy procedures. Interventional cardiology represents a niche but emerging segment, where biopsy techniques are used for specific cardiac conditions. Other applications represent a growing segment, including gastroenterology and pulmonology, broadening the use of biopsy devices.

By Biopsy Type
Needle-based biopsy represents the dominant segment, driven by its minimally invasive nature, cost-effectiveness, and widespread adoption across multiple diagnostic procedures. MRI-based biopsy also represents a significant segment, supported by its high precision and effectiveness in detecting lesions not visible through other imaging techniques. Stereotactic biopsy represents an important segment, particularly in breast cancer diagnosis, offering accurate tissue sampling using imaging guidance. X-ray-based biopsy represents a steady segment, widely used in conventional diagnostic settings. Others represent a growing segment, including ultrasound-guided and advanced hybrid biopsy techniques, enhancing diagnostic accuracy and patient outcomes.

By End User
Hospitals represent the dominant segment, as they are primary centers for advanced diagnostic procedures and equipped with comprehensive imaging and biopsy technologies. Cancer hospitals also represent a significant segment, driven by the increasing burden of cancer and the need for specialized diagnostic and treatment facilities. Research centres represent an important segment, contributing to advancements in biopsy technologies and clinical studies, supporting innovation and improved diagnostic methods.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a market research and consulting firm that provides end-to-end business solutions to organizations from research to consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology, ensuring that our clients receive tailored insights that address their specific business challenges and objectives.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.